Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (OTCQB:
$CBDY) (TSXV: $HVT.V) (CSE: $JANE.C) (TSXV: $PCLO.V) (CSE: $EURO.C)
Delta, Kelowna, BC –August 13,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/08131CBDY-HVT-JANE-PCLO-EURO.asp
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of
Investorideas.com "Potcast" featuring cannabis news, stocks to watch
as well as insights from thought leaders and experts.
In
today’s podcast we look at a few early announcements.
But first, Grenco Science, the leader in advanced technology
cannabis vaporization, announces a joint venture with Vapium, the award-winning vaporization company
and resident of Johnson & Johnson Innovation - JLABS (JLABS), and investee
of Canopy Growth. The companies will work together to integrate ground-breaking
technologies for the medical cannabis industry under the brand name Accudose. The
first-of-its-kind cannabis consumption platform will fill a void in the market
for an accurate, dosing protocol that will allow practitioners to prescribe
cannabis as medicine, reframing cannabis consumption.
"Grenco
Science is excited to partner with Vapium and bring Accudose into our growing
portfolio of brand partners. After seeing the technology Vapium created, this
was a clear fit for the multi-state model we developed to launch the Gio. This
partnership will allow us to introduce a product offering into the medical
cannabis industry with the first actual accurate dosing technology which has
not yet been seen on the market and will propel Accudose to become a leader in
the industry," said Chris Folkerts, CEO and Founder of Grenco
Science.
"From
the inception of Vapium, our primary focus has always been
patient-centric," said Michael Trzecieski, Vapium co-founder and CEO.
"We've worked hard to fully consider the medical conditions faced by users
and created a revolutionary platform that will empower patients and
practitioners and we are thrilled to be launching this with Grenco so that the
world will benefit. Grenco's multi state filling ecosystem coupled with their
international brand recognition is nothing short of remarkable. Combining this
infrastructure with our years of medical research, dosing and analytic
capabilities, we are uniquely positioned to drive the transparency and efficacy
needed to standardize cannabis as medicine."
Under
the terms of the partnership, the parties will integrate Vapium's innovative
dose control technologies and hardware with new cannabis products from Grenco
Science's diverse portfolio of brand partners, which include Caliva, Eaze,
FlowerOne, Harvest Health and Old Pal among others, to bring to market the
revolutionary, accurate dose-metered cannabis consumption platform.
Target Group Inc. (OTCQB:
CBDY) announced that
effective August 8, 2019, it has entered into an exclusive licensing,
manufacturing and distribution agreement with cGreen Inc. for a period of 10
years. The agreement permits Target Group to manufacture and distribute the
patent-pending THC antidote, True Focus™, in the United States, Europe and the
Caribbean.
The exclusive licensing agreement grants
Target Group the rights to the complete True Focus™ intellectual property
portfolio, including use of the "True Focus™" trade name, trademarks,
logos and art, rights to product formulations, methods and processes. The
agreement will facilitate the expansion of Target Group's growing wellness
portfolio and position the Company for global manufacturing and distribution.
Excessive cannabis consumption may lead
to adverse and unwanted side effects. True Focus' all-natural, nutraceutical
formulation offers a unique solution to rapidly alleviate the undesirable
effects associated with over-consumption of tetrahydrocannabinol
("THC"). True Focus' innovative THC antidote is dispensed
sublingually via a discreet, pocket-sized spray bottle. True Focus' product
formulations are considered 'patent-pending' by way of a United States Patent
and Trademark Office ("USPTO") application.
"The True Focus agreement will
enable Target Group to enter legal, international markets around the globe, and
to develop a centralized distribution channel for its suite of wellness
products. This partnership also accelerates Target Group's ability to generate
revenue within the broader American, European and Caribbean markets immediately",
said Rubin Schindermann, Chief Executive Officer for Target Group.
Harvest One Inc. (TSXV:
HVT) (OTCQX:
HRVOF), through
its wholly-owned subsidiary Satipharm Ltd. today
announced positive results of a Phase 2 clinical
trial of its CBD GelPell® capsules in the management of Treatment
Resistant Epilepsy (TRE) have been published in Epilepsy & Behaviour, a
bimonthly peer-reviewed medical journal covering behavioral aspects of epilepsy.
Some
of the highlights included:
●
Phase 2 open label clinical trial is
aimed at measuring safety and efficacy of Satipharm CBD capsules for reducing
seizure frequency in children with refractory, or treatment-resistant, epilepsy
●
The median reduction of monthly seizures
was -82% in the 12-week treatment period in treatment-resistant children when
added to current medications
●
56% who started the treatment had a
reduction of at least 50% in total number of seizures during the entire
treatment period, compared to observation
●
73% were rated as "very much
improved/improved" in overall condition on the Caregiver Global Impression
of Improvement scale
●
82% were rated as "very much
reduced/reduced"
●
A mean 73.4% reduction from baseline
monthly seizure frequencies was observed
●
Two patients were fully seizure-free
within 5 weeks of treatment
●
An additional seven patients reported
>50% seizure frequency reduction
A
fulsome description of the study and results can be found in the Harvest One
background document available on our website at https://www.harvestone.com/portfolio/satipharm/#clinical-trials
"The
results of our second stage of clinical trials on our Satipharm 50mg CBD
GelPell® products are very encouraging for the patients we serve,
our shareholders and our company" said Grant Froese, Chief Executive
Officer of Harvest One. "We continue to be focused on the best in class
health, wellness, and self-care products at Harvest One and we believe that our
unique products, including the proprietary GelPell®, will be highly
sought after as cannabis legalization takes hold around the world".
GelPell®
capsules contain full spectrum hemp extract CBD in a seamless gelatine bead.
This bead is placed inside a hard gastro-resistant capsule ensuring the release
of CBD in the small intestine where it has the greatest effect. Manufactured in
Switzerland and EU GMP Certified, every 50mg GelPell® capsule has
been clinically proven to improve the body's absorption of CBD and other
cannabinoids. They are easy to take and contain a consistent and precise dose
of CBD.
"The
efficacy of Satipharm's CBD capsules as an add-on therapy in the treatment of
pediatric, intractable epilepsy has been shown. Moreover, these results compare
favourably to other similar studies of cannabidiol" said Prof. Uri Kramer,
Director of Pediatric Epilepsy Service, Tel Aviv Sourasky Medical Centre and
Principal Investigator of the trial. "Importantly, the significant
reductions in seizure frequency while demonstrating satisfactory safety and
tolerability profile, in these very difficult to treat patients, have the
potential to be a life-altering event for these patients and their families. I
would be greatly interested in prescribing such standardized and clinically
tested product as Satipharm's 50mg CBD GelPell®".
Mojave Jane Brands (CSE:
JANE) (OTC:
HHPHF), a California cannabis company, announced that
it is entering the market for cannabis-infused beverages by signing a
Manufacturing License Agreement with Vancouver-based HAI Beverages Inc.
The Agreement allows Mojave Jane to
exclusively license HAI's proprietary technology for the solubility and
bioavailability of THC and CBD components in the State of California. The
Company will use this technology in the formation process of flavorless
distillates and concentrates produced specifically for non-alcoholic beverage
products as a micro-dosage offering.
Advantages of HAI's proprietary
technology:
●
Allows the body to absorb THC and CBD
components immediately, producing desired effects in a matter of minutes and
enabling a much better control of dosages both for wellness and recreational
purposes.
●
Enables precise and predictable dosages.
●
While producing a similar effect as an
alcoholic beverage, a 12 oz micro-dosed drink, for example, can be enjoyed
without negative side effects such as feeling hungover, causing liver damage,
ingesting empty calories or remaining in the system for extended periods at a
time.
●
Neutral in taste for versatile
applications.
●
Bio-available concentrates in CBD or THC
formulation.
Mojave Jane's CEO Gary Latham comments:
"While this is a big step in the
evolution of cannabis products for recreational and wellness consumers, it is
an even bigger move for Mojave Jane as we now enter California's massive
beverage market. The license also allows us to produce an "additive"
that can be marketed to other beverage producers, expanding this opportunity to
the State's even larger adult beverage market.”
“We truly recognize this Agreement with
HAI as an ideal match: The flexibility of HAI's technology lets us manufacture
products that create custom effects catering to the specific needs of various
consumer demographics. From HAI's perspective, they gain access to the
California cannabis and adult beverage market since ingestible CBD and THC
products based on their technology can only be produced in a licensed cannabis
manufacturing facility like ours. I am looking forward to working with the HAI
team on the integration process and as we explore the enormous potential of
this opportunity together."
PharmaCielo
Ltd. (TSXV:PCLO) (OTC:PHCEF), the
Canadian parent of Colombia's premier cultivator and producer of
medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced
it has signed a sales agreement with Uruguay-based Laboratorios Adler.
According to the agreement, PharmaCielo will provide Adler with bulk CBD
extracts, bulk and bottled CBD oils and veterinary products that will be sold
by Adler in Uruguay, Paraguay, Bolivia and Southern Brazil.
The four-and-a-half-year agreement with
option for renewal signals PharmaCielo's foray into the high-growth veterinary
CBD treatment and wellness market. This is also the first collaboration between
PharmaCielo and Creso Pharma that includes sub-contracting to Creso the
responsibility for manufacture and supply of Creso's veterinary feed products,
anibidiol® 2.5 and anibidiol® 8, with export approval
received from the Swiss Cantonal regulator.
"This exciting entry into the animal
health marketplace through the agreement with Adler is an example of
PharmaCielo executing on its strategic objectives to supply both bulk oil and
proprietary products to customers using established large chain
distributors," said David Attard, CEO with PharmaCielo Ltd.
"Including Creso Pharma's animal health products also demonstrates both
the mutual strategic value of our Creso acquisition proposal, which will be
fully realized upon completion of the transaction, and the value of branded,
fully manufactured product to provide enhanced margin opportunity. We are
thrilled about the potential this agreement brings to all parties, and we look
forward to working with our Latin American and European partners."
A manufacturer and importer of products
for animal treatment, Laboratorios Adler services a wide range of customers
from pet shops to veterinary clinics and wholesale distributors of veterinary
products. The CBD-based products that Adler will distribute in its area are
designed for trauma pain and cancer-related pain treatment for domestic and
large animals.
"We are seeing increased demand for
CBD-based veterinary products across all our markets as customers look for
natural solutions to address pain, stress and a variety of other ailments in
both domestic and large animals," said Adriana Adler, Chief Financial Officer with Laboratories Adler S.A.
"Partnering with PharmaCielo gives us an incredible advantage in this
rapidly developing category. Creso Pharma's anibidiol® line of
products, targeting stress, behavioral problems and chronic pain, along with
PharmaCielo's CBD isolate, among the purest and highest quality we've seen,
make a great addition to our product portfolio."
EuroLife Brands Inc. (formerly Cannvas MedTech Inc.) (CSE:
EURO) (OTCPK:
CANVF), a leading digital cannabis education
and analytics company, announced that,
further to its news release of July 31, 2019, it has completed its name change
from "Cannvas MedTech Inc." to "EuroLife Brands Inc." to
better reflect the direction of the Company's business.
"We are tremendously excited to
complete our company rebrand and continue to leverage our unbiased cannabis
education resources to better support the global cannabis community and bring
additional value to our shareholders," said Steve Loutskou, Chief
Operating Officer, Global Markets, EuroLife Brands. "We are confident that
coupling our cannabis education with an exclusive CPG marketplace for
discerning cannabis consumers across Europe and South America will meet and
exceed their expectations of product selection and overall awareness."
The Company's trading symbol on the
Canadian Securities Exchange (the "CSE")
has changed to "EURO" and, on the OTC Pink Sheets (the "OTCPK"), remain "CANVF"
until the pending symbol change has been approved. The trading symbol will
remain as "3CM" on the Frankfurt Stock Exchange. The Company's new
CUSIP number for its common shares is 29876F106 and ISIN is CA29876F1062.
The Company has been advised by the CSE
that the common shares will commence trading under the new name, effective at
the opening of trading on August 14, 2019. In the coming days, all the
Company's digital properties will be updated to reflect new EuroLife branding.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
